FDA recall D-1659-2019
RXQ Compounding LLC · Class II · drug
Product
FENTANYL 2MCG/ML BUPIVACAINE 0.125% IN NACL 0.9% SRY C-II, 50ML per syringe (C-II) RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0207-89
Reason for recall
Lack of Assurance of Sterility
Distribution
Nationwide USA
Key facts
- Status
- Terminated
- Initiation date
- 2019-06-19
- Report date
- 2019-08-14
- Termination date
- 2022-09-16
- Voluntary/Mandated
- Voluntary: Firm initiated
- Location
- Athens, OH, United States
Primary source
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1659-2019